Home » Stocks » IRMD

IRadimed Corporation (IRMD)

Stock Price: $23.08 USD -0.92 (-3.83%)
Updated Mar 8, 2021 1:10 PM EST - Market open
Market Cap 294.47M
Revenue (ttm) 31.72M
Net Income (ttm) 1.37M
Shares Out 12.28M
EPS (ttm) 0.11
PE Ratio 209.82
Forward PE 49.51
Dividend n/a
Dividend Yield n/a
Trading Day March 8
Last Price $23.08
Previous Close $24.00
Change ($) -0.92
Change (%) -3.83%
Day's Open 24.00
Day's Range 22.45 - 24.00
Day's Volume 30,169
52-Week Range 14.41 - 26.31

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 1 month ago

WINTER SPRINGS, Fla., Jan. 27, 2021 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2020 fourth quarter financial results before the m...

GuruFocus - 2 months ago

The S&P 500 Index stocks saw their aggregate trailing 12-month real revenue per share rise at a compound average growth rate (CAGR) of 1.97% per annum over the past five years, which occurred ...

Other stocks mentioned: EXPI, FLNT
Seeking Alpha - 4 months ago

IRadimed Corporation (IRMD) CEO Roger Susi on Q3 2020 Results - Earnings Call Transcript

Seeking Alpha - 4 months ago

IRadimed Corporation's (IRMD) CEO Roger Susi On Q3 2020 Results - Quick Version Earnings Call Transcript

Zacks Investment Research - 4 months ago

iRadimed (IRMD) delivered earnings and revenue surprises of 120.00% and 3.20%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire - 4 months ago

WINTER SPRINGS, Fla., Oct. 30, 2020 (GLOBE NEWSWIRE) -- iRadimed Corporation (the “Company”) (NASDAQ: IRMD), a leader in the development of innovative magnetic resonance imaging (“MRI”) medica...

Zacks Investment Research - 4 months ago

IRadimed (IRMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 5 months ago

WINTER SPRINGS, Fla., Oct. 08, 2020 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2020 third quarter financial results before the ma...

Seeking Alpha - 7 months ago

IRadimed Corp (IRMD) CEO Roger Susi on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 7 months ago

iRadimed (IRMD) delivered earnings and revenue surprises of 225.00% and 22.96%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire - 7 months ago

WINTER SPRINGS, Fla., July 30, 2020 (GLOBE NEWSWIRE) -- iRadimed Corporation (the “Company”) (NASDAQ: IRMD), a leader in the development of innovative magnetic resonance imaging (“MRI”) medi...

Zacks Investment Research - 7 months ago

IRadimed (IRMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 7 months ago

WINTER SPRINGS, Fla., July 16, 2020 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2020 second quarter financial results before the...

GlobeNewsWire - 9 months ago

WINTER SPRINGS, Fla., May 29, 2020 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD), announced today that its Board of Directors has appointed Roger Susi to resume his duties as the C...

GlobeNewsWire - 9 months ago

Latest patent expands previous claims around IRADIMED’s wireless communication as used to remotely control an IV pump Latest patent expands previous claims around IRADIMED’s wireless communica...

Seeking Alpha - 10 months ago

IRadimed's (IRMD) CEO Leslie McDonnell on Q1 2020 Results - Earnings Call Transcript

Zacks Investment Research - 10 months ago

iRadimed (IRMD) delivered earnings and revenue surprises of 50.00% and -0.48%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Benzinga - 10 months ago

Shares of iRadimed (NASDAQ:IRMD) rose 0.2% after the company reported Q1 results.

Zacks Investment Research - 10 months ago

IRadimed (IRMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 11 months ago

Expects first quarter 2020 revenue of $8.6 million to $8.7 million Expects first quarter 2020 revenue of $8.6 million to $8.7 million

Seeking Alpha - 1 year ago

IRadimed's (IRMD) CEO Leslie McDonnell on Q4 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

iRadimed (IRMD) delivered earnings and revenue surprises of 50.00% and -0.63%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 1 year ago

IRadimed (IRMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 1 year ago

WINTER SPRINGS, Fla., Jan. 07, 2020 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced the retirement of Brent Johnson, Executive Vice President of Worldwide Sales and Marketi...

Seeking Alpha - 1 year ago

These companies are somewhere past proof of concept and on the road to profitability or already profitable.

Other stocks mentioned: FLYLF, GNSS, OSSIF, SYATF, ZYXI
GlobeNewsWire - 1 year ago

WINTER SPRINGS, Fla., Dec. 12, 2019 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD), a leader in the development of innovative magnetic resonance imaging (“MRI”) medical devices and ...

Seeking Alpha - 1 year ago

IRADIMED Corporation (IRMD) CEO Leslie McDonnell on Q3 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

iRadimed (IRMD) delivered earnings and revenue surprises of 53.33% and 1.15%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire - 1 year ago

WINTER SPRINGS, Fla., Oct. 30, 2019 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD), a leader in the development of innovative magnetic resonance imaging (“MRI”) medical devices and ...

Seeking Alpha - 1 year ago

IRMD will soon report record revenue and improving margins for a fourth consecutive quarter.

GlobeNewsWire - 1 year ago

WINTER SPRINGS, Fla., Oct. 08, 2019 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD), today announced that it received a close-out letter from the U.S. Food and Drug Administration re...

Seeking Alpha - 1 year ago

IRadimed is a leader in developing innovative MRI (Magnetic Resonance Imaging) compatible medical devices and accessories.

GlobeNewsWire - 1 year ago

WINTER SPRINGS, Fla., Aug. 27, 2019 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD), today announced that Leslie McDonnell, President and Chief Executive Officer, Roger Susi, Chairma...

Seeking Alpha - 1 year ago

IRadimed Corp (IRMD) CEO Roger Susi on Q2 2019 Results - Earnings Call Transcript

Seeking Alpha - 1 year ago

IRMD is the only known provider of non-magnetic MRI compatible products in the U.S.

Seeking Alpha - 1 year ago

IRadimed Corp (IRMD) CEO Roger Susi on Q1 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

IRadimed (IRMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

About IRMD

IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices, and related accessories and services in the United States and internationally. It offers MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; and MRI compatible patient vital signs monitoring system. The company also provides IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring with sensors and accessories. It... [Read more...]

Industry
Medical Devices
IPO Date
Jul 16, 2014
CEO
Leslie McDonnell
Country
United States
Stock Exchange
NASDAQ
Ticker Symbol
IRMD
Full Company Profile

Financial Performance

In 2020, IRadimed's revenue was $31.72 million, a decrease of -17.65% compared to the previous year's $38.52 million. Earnings were $1.37 million, a decrease of -85.79%.

Financial Statements

Analyst Forecasts

According to one analyst, the rating for IRadimed stock is "Buy" and the 12-month stock price forecast is 29.00.

Price Target
$29.00
Analyst Consensus: Buy